CytoDyn has engaged Syneos Health as the contract research organization for its upcoming Phase II study exploring leronlimab and its effects on chronic inflammation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYDY:
- CytoDyn completes FDA meeting on Phase II Study of leronlimab
- CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
- CytoDyn Resolves Lawsuit, Secures Payments, and Clears Debt
- CytoDyn announces settlement with Amarex Clinical Research
- CytoDyn Announces Settlement with Amarex Clinical Research LLC